[go: up one dir, main page]

MX2021010043A - Uso de nicotinamida ribósido, ácido nicotinico ribósido, compuestos de nicotinil ribósido reducido y derivados de compuestos de nicotinil ribósido en formulaciones. - Google Patents

Uso de nicotinamida ribósido, ácido nicotinico ribósido, compuestos de nicotinil ribósido reducido y derivados de compuestos de nicotinil ribósido en formulaciones.

Info

Publication number
MX2021010043A
MX2021010043A MX2021010043A MX2021010043A MX2021010043A MX 2021010043 A MX2021010043 A MX 2021010043A MX 2021010043 A MX2021010043 A MX 2021010043A MX 2021010043 A MX2021010043 A MX 2021010043A MX 2021010043 A MX2021010043 A MX 2021010043A
Authority
MX
Mexico
Prior art keywords
riboside
compounds
nicotinyl
nicotinamide
nicotinic acid
Prior art date
Application number
MX2021010043A
Other languages
English (en)
Inventor
Matthew Roberts
Aron Erickson
Amanda Storjohann
Philip Redpath
Original Assignee
Chromadex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chromadex Inc filed Critical Chromadex Inc
Publication of MX2021010043A publication Critical patent/MX2021010043A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/13—Nucleic acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/148—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/048—Pyridine radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Zoology (AREA)
  • Physiology (AREA)
  • Biophysics (AREA)
  • Botany (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pediatric Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Saccharide Compounds (AREA)
  • Non-Alcoholic Beverages (AREA)
  • Medicinal Preparation (AREA)
  • General Preparation And Processing Of Foods (AREA)

Abstract

Se proporcionan métodos para estabilizar o encapsular al menos un compuesto seleccionado del grupo que consiste en nicotinamida ribósido (NR), ácido nicotinico ribósido (NAR), nicotinamida mononucleótido (NMN), ácido nicotinico mononucleótido (NaMN), derivados de los mismos, o sales de los mismos. También. se proporcionan composiciones que incluyen gránulos de cera, formas estabilizadas o encapsuladas de al menos un compuesto seleccionado del grupo que consiste en nicotinamida ribósido (NR), ácido nicotinico ribósido (NAR) y nicotinamida mononucleótido (NMN), derivados de los mismos, o sales de los mismos.
MX2021010043A 2019-02-21 2020-02-21 Uso de nicotinamida ribósido, ácido nicotinico ribósido, compuestos de nicotinil ribósido reducido y derivados de compuestos de nicotinil ribósido en formulaciones. MX2021010043A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962808802P 2019-02-21 2019-02-21
PCT/US2020/019361 WO2020172629A1 (en) 2019-02-21 2020-02-21 Use of nicotinamide riboside, nicotinic acid riboside, reduced nicotinyl riboside compounds, and nicotinyl riboside compound derivatives in formulations

Publications (1)

Publication Number Publication Date
MX2021010043A true MX2021010043A (es) 2022-07-19

Family

ID=72141418

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021010043A MX2021010043A (es) 2019-02-21 2020-02-21 Uso de nicotinamida ribósido, ácido nicotinico ribósido, compuestos de nicotinil ribósido reducido y derivados de compuestos de nicotinil ribósido en formulaciones.

Country Status (11)

Country Link
US (1) US12485134B2 (es)
EP (1) EP3927715A4 (es)
JP (1) JP2022522114A (es)
KR (1) KR20220013540A (es)
CN (1) CN113727987A (es)
AU (1) AU2020224158A1 (es)
BR (1) BR112021016432A2 (es)
CA (1) CA3130704A1 (es)
MX (1) MX2021010043A (es)
WO (1) WO2020172629A1 (es)
ZA (1) ZA202106912B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220088045A1 (en) * 2020-09-23 2022-03-24 Mo S. Kharazmi Treatment compositions
EP4284388A4 (en) * 2021-01-29 2024-12-18 Chromadex, Inc. ETHYLCELLULOSE-BASED COATINGS FOR THE MICROENCAPSULATION OF NICOTINAMIDE DRIBOSIDE AND OTHER NICOTINAL DRIBOSIDE COMPOUNDS
CN113181205B (zh) * 2021-04-19 2023-07-14 苏州人本药业有限公司 包括nmn的药物组合物及其应用
WO2022263505A1 (en) * 2021-06-16 2022-12-22 Société des Produits Nestlé S.A. Methods of solid phase wax coating of an active ingredient
CN119097617A (zh) * 2021-10-26 2024-12-10 成都拂尔医药科技有限公司 一种双黄纳米颗粒及其制备与应用
CN115232184B (zh) * 2021-12-06 2024-07-05 宁波熙健医药科技有限公司 呋喃核糖基吡啶衍生物及其药物组合物和用途
CN114191329B (zh) * 2021-12-17 2023-05-12 百瑞全球有限公司 口腔护理添加剂、口腔护理组合物、制备方法、成套用具及其应用
WO2023119230A1 (en) 2021-12-22 2023-06-29 L'oreal Coagulation pathway and nicotinamide-adenine dinucleotide pathway modulating compositions and methods of their use
CN114509465B (zh) * 2022-02-14 2025-04-22 中国检验检疫科学研究院 一种β-烟酰胺单核苷酸及其相关物质的检测方法和应用
CA3252814A1 (en) * 2022-05-11 2023-11-16 Tecton Group, Llc SYSTEMS AND METHODS FOR ENCAPSULATING SMALL MOLECULES
CN119947599A (zh) * 2022-09-30 2025-05-06 株式会社明治 用于促进婴童脑功能发育的组合物
CN115948365B (zh) * 2022-12-09 2023-08-04 华南理工大学 一种烟酰胺核苷激酶及其编码基因与应用
CN121152567A (zh) * 2023-05-12 2025-12-16 明治控股股份有限公司 用于促进儿童的发育的组合物
JP7556178B1 (ja) 2023-07-28 2024-09-25 ワダカルシウム製薬株式会社 経口製剤
CN118593362A (zh) * 2024-06-26 2024-09-06 山东福瑞达生物股份有限公司 一种nmn油悬液的制备方法与应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5213810A (en) 1990-03-30 1993-05-25 American Cyanamid Company Stable compositions for parenteral administration and method of making same
ATE134873T1 (de) 1991-07-23 1996-03-15 American Cyanamid Co Stabile zusammensetzungen für parenterale verabrechung und ihre verwendung
EP1616562A1 (en) 1999-06-07 2006-01-18 ALTANA Pharma AG Novel preparation and administration form comprising an acid-labile active compound
US20070053858A1 (en) * 2001-03-22 2007-03-08 Tanner Paul R Personal care composition
US20030232091A1 (en) * 2002-06-17 2003-12-18 Adi Shefer Stabilized retinol for cosmetic dermatological, and pharmaceutical compositions, and use thereof
MXPA06002062A (es) * 2003-08-22 2006-05-19 Danisco Microcapsulas.
PL2034973T5 (pl) 2006-06-22 2023-02-20 Dsm Ip Assets B.V. Kapsułkowane kompozycje nietrwałych związków i sposoby ich wytwarzania
TW200824582A (en) * 2006-08-29 2008-06-16 Martek Biosciences Corp Use of DPA(n-6) oils in infant formula
US20110091553A1 (en) * 2008-06-02 2011-04-21 Kaneka Corporation Method for producing microcapsules using solid fat
WO2015127007A1 (en) 2014-02-19 2015-08-27 Perdue Agribusiness Llc Compositions and methods for embedding nutrients
CN106715455A (zh) 2014-06-06 2017-05-24 葛兰素史密斯克莱知识产权（第2 号）有限公司 烟酰胺核苷类似物及其药物组合物和用途
US10323058B2 (en) 2014-07-24 2019-06-18 W. R. Grace & Co.-Conn. Crystalline form of nicotinamide riboside
WO2016149277A1 (en) * 2015-03-17 2016-09-22 Specialty Nutrition Group, Inc. Nutritional compositions to enhance mitochondrial energy production
WO2017004100A1 (en) 2015-06-29 2017-01-05 The Procter & Gamble Company Encapsulated particles comprising nicotinamide riboside
WO2017004101A1 (en) 2015-06-29 2017-01-05 The Procter & Gamble Company Skin care compositions comprising particles with nicotinamide riboside and methods of using the same
ITUB20153652A1 (it) 2015-09-16 2017-03-16 Fatro Spa Microsfere contenenti lattoni macrociclici antielminitici
MX2018012527A (es) * 2016-04-14 2019-08-21 Chromadex Inc Uso de ribosido de nicotinamida, ribosido de acido nicotinico, mononucleotido de nicotinamida y derivados de compuestos nicotinoílo en formula para lactantes.
CN109640984A (zh) * 2016-04-20 2019-04-16 可劳迈戴斯有限公司 烟酸核苷或烟酰胺核苷衍生物及其还原的衍生物作为增加nad+的前体的用途

Also Published As

Publication number Publication date
US20200268778A1 (en) 2020-08-27
BR112021016432A2 (pt) 2021-11-09
ZA202106912B (en) 2023-07-26
NZ779753A (en) 2025-08-29
WO2020172629A1 (en) 2020-08-27
CA3130704A1 (en) 2020-08-27
EP3927715A4 (en) 2023-03-01
WO2020172629A8 (en) 2021-04-08
CN113727987A (zh) 2021-11-30
US12485134B2 (en) 2025-12-02
KR20220013540A (ko) 2022-02-04
JP2022522114A (ja) 2022-04-14
EP3927715A1 (en) 2021-12-29
AU2020224158A1 (en) 2021-09-30

Similar Documents

Publication Publication Date Title
MX2021010043A (es) Uso de nicotinamida ribósido, ácido nicotinico ribósido, compuestos de nicotinil ribósido reducido y derivados de compuestos de nicotinil ribósido en formulaciones.
PH12019502048A1 (en) Pyrimidinium compounds and their mixtures for combating animal pests
CY1123663T1 (el) Πυριμιδινονες ως αναστολεις τελεστη χια
JOP20210272A1 (ar) مركبات دايازين - أميد نشطة بشكل مبيد للآفات
CY1122870T1 (el) Νεα πιπεριδινυλ παραγωγα, μεθοδος για παρασκευη αυτων και φαρμακευτικες συνθεσεις που τα περιεχουν
MX379536B (es) Compuestos de pirimidinio sustituido y derivados para combatir plagas de animales.
PH12018502516A1 (en) New (hetero)aryl-substituted-piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them
MX2018012527A (es) Uso de ribosido de nicotinamida, ribosido de acido nicotinico, mononucleotido de nicotinamida y derivados de compuestos nicotinoílo en formula para lactantes.
MX2014011829A (es) Compuestos de piridinilideno n-sustituidos y derivados para combatir plagas de animales.
TN2017000357A1 (en) Substituted nucleoside derivatives useful as anticancer agents
MX2017015496A (es) Fosforilacion selectiva sin disolvente.
MX2018004358A (es) Restablecimiento de rutas biológicas para defender contra el deterioro por el envejecimiento humano y repararlo.
MY186830A (en) A novel carystalline from of a benzimidazole derivative and a preparation method thereof
BR112016001774A2 (pt) métodos de preparação de ribosídeo de nicotinamida e seus derivados
NZ602800A (en) 6-acyl-1,2,4-triazine-3,5-dione derivative and herbicides
MY199735A (en) Jak1 selective inhibitors
EA201990279A1 (ru) Гербицидные композиции, содержащие фенилпиримидины
GEAP202115351A (en) Novel, highly active amino-thiazole substituted indole-2-carboxamides active against the hepatitis b virus (hbv)
MX2019012454A (es) Compuesto solido cristalino novedoso de clorhidrato de 3-fenil-4-propil-1-(piridin-2-il)-1h-pirazol-5-ol.
MX2016016538A (es) Derivados de quinazolinona como inhibidores de fosfatidilinositol 3-cinasa.
BR112017022654A2 (pt) derivado heterocíclico de 6 membros e composição farmacêutica compreendendo o mesmo
NZ719968A (en) Pesticidal compositions and related methods
NZ719952A (en) Pesticidal compositions and related methods
PH12022552177A1 (en) Heteroaryl heterocyclic compounds and uses thereof
EA202090500A1 (ru) Кристаллические формы иммуномодуляторов